Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels

Addiction Biology

Volumn 8, Issue 2, 2003, Pages 211-217

  Foster, John ^a   Brewer, Colin ^b   Steele, Terry ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Stapleford Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; NALTREXONE;

ABSTINENCE; ADULT; ARTICLE; COHORT ANALYSIS; DRUG DETOXIFICATION; FEMALE; HUMAN; IMPLANT; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; TISSUE REACTION;

ADULT; COHORT STUDIES; DRUG ADMINISTRATION ROUTES; FEMALE; FOLLOW-UP STUDIES; HEROIN; HEROIN DEPENDENCE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PILOT PROJECTS; PREVALENCE; PROSTHESES AND IMPLANTS; RECURRENCE;

EID: 0037810374     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/1355621031000117446     Document Type: Article

References (26)

1. Gossop M, Green L, Phillips G. What happens to opiate addicts immediately after treatment: a prospective follow-up study. Br Med J 1987;294:1377-80.
2. Bearn J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 1998;50:227-32.
3. Gossop M, Johns A, Green L, et al. Opiate withdrawal: in-patient versus out-patient programmes and preferred versus random assignment to treatment. Br Med J 1987;293:103-4.
4. Gossling HW, Gunkel S, Schneider U, Melles W. [Frequency and causes of premature termination during in-patient opiate detoxification.] Fortschr Neurol Psychiatrie 2001;69:474-81.
5. Chan KY. The Singapore naltrexone community-based project for heroin addicts compared with a drug-free community-based programme: the first cohort. J Clin Forens Med 1996;3:87-92.
6. Cornish JW, Metzger D, Woody GE, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 1997;14,6:529-34.
7. Gerra G, Marcato A, Caccavari R, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995;12:35-41.
8. Beaini AY, Johnson TS, Langstaff P, Carr MP, Crossfield JN, Sweeney RC. A compressed opiate detoxification regime with naltrexone maintenance: patient tolerance, risk assessment and abstinence rates. Addict Biol 2000;5:451-62.
9. Azrin NH, Sissons RW, Mayer SR, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry 1982;13:105-12.
10. Brewer C. On the specific effectiveness, and undervaluing, of pharmacological treatments for addiction: a comparison of methadone, naltrexone and disulfiram with psychosocial interventions. Addict Res 1996;3:297-313.
11. Brewer C, Meyers RJ, Johnsen J. Does disulfiram help to prevent relapse in alcohol abuse? CNS Drugs 2000;14:329-41.
12. Buntwal N, Bearn J, Gossop M, Strang J. Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. Drug Alcohol Depend 2000;59:183-8.
13. Laheij RJF, Krabbe PFM, De Jong CAJ. Rapid heroin detoxification under general anaesthesia. JAMA 2000;283:1143.
14. Chiang CN, Hollister LE, Kishimoto A, Barnett G. Kinetics of a naltrexone sustained-release preparation. Clin Pharmacol Ther 1984;36:704-8.
15. Office of Population Censuses and Surveys. Classification of occupations and coding index. London: HMSO, 1991.
16. Carreno Rendueles JE, Ortiz Jackson R, Sanchez del Rio J, Alvarez Diaz CE, Calvo Rodrigues JR, Perez Gonzalez SF. Pautas de induccion rapida. Modelos ambulatorios en Asturias. Psiquiat Biol 1996;13:207-16.
17. Carreno JE, Bobes J, Brewer C, et al. 24 hour opiate detoxification and antagonist induction at home - the 'Asturian Method': a report on 1368 procedures. Addict Biol 2002;7:243-50.
18. Ebel K, Schachtel U, Partecke L. Histological findings after repeatedly implanted naltrexone pellets. Paper presented at the 6th Stapleford International Symposium, Rapid opiate detoxification under anaesthesia or sedation and post-detox management using naltrexone. Berlin, 17-18 June 1999.
19. Brewer C, Gastfriend D. Rapid opioid detoxification. JAMA 1998;279:1872.
20. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol 2002;7:321-3.
21. Porter SJ, Somogyi AA, White JM. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. Addict Biol 2002;7:219-25.
22. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 2002;159:351-60.
23. Lee MC, Wagner HN Jr, Tanada S, Frost JJ, Bice AN, Dannals RF. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1988;29:1207-11.
24. Verebey K, Volavka J, Mule S, Resnick R. Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315-28.
25. O'Neil G, Hulse GK. A possible role for implantable naltrexone in the management of the 'high risk' pregnant heroin user. Aust NZ J Obstet Gynaecol 2002;42:93-4.
26. Gölz J, Partecke G. Katamnesticher entwicklung opiatabhängiger nach naltrexon-induzierten entzug unter narcose, naltrexongestutzter rückfallprophylaxe und ambulanter psychosozialer nachsorge [Progress of heroin addicts after naltrexone-induced detoxification under anaesthesia, naltrexone-based relapse prevention and out-patient psychosocial follow-up care]. Sücttherapie 2000; 1:166-72.